Current Headlines
-
Vertex Announces FDA Clearance Of Investigational New Drug Application For VX-407 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
3/21/2024
Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants.
-
Cabaletta Bio Announces FDA Granted Orphan Drug Designation To CABA-201 For Treatment Of Systemic Sclerosis
3/21/2024
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, for the treatment of systemic sclerosis (SSc).
-
High Speed Protein Movies To Aid Drug Design
3/21/2024
Researchers from the University of Southampton have developed technology to help scientists observe proteins in motion. Understanding how proteins move will allow novel drugs to be designed.
-
IPA Acquires The Carterra LSA Instrument To Enhance Antibody Discovery And Bolster Its AI Developments
3/20/2024
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) an artificial intelligence-driven biotherapeutic research and technology company, today announced that it has acquired the LSA instrument platform from Carterra, a leading provider of high-throughput large and small molecule screening and characterization solutions.
-
Semarion Introduces SemaCyte Multiplexing Platform To Enhance Cell Assay Data Quality And Speed During Drug Discovery
3/20/2024
Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today introduced its SemaCyte Multiplexing Platform, an expansion to the existing SemaCyte Microcarrier platform to utilize optical barcoding to accelerate screening processes during in vitro drug discovery.
-
Takeda Announces U.S. FDA Approval Of Supplemental New Drug Application (sNDA) For ICLUSIG (Ponatinib) In Adult Patients With Newly Diagnosed Ph+ ALL
3/19/2024
Takeda today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
-
DNAnexus Adds NVIDIA NIM And CUDA-X Microservices To Precision Health Data Cloud To Accelerate Drug Discovery And Improve Patient Care
3/19/2024
DNAnexus, Inc., the provider of the Precision Health Data Cloud, today announced that it is integrating new NVIDIA NIM and CUDA-X microservices.
-
Cognizant To Apply Generative AI To Enhance Drug Discovery For Pharmaceutical Clients With NVIDIA BioNeMo
3/19/2024
Cognizant (NASDAQ: CTSH) is advancing the application of generative AI (gen AI) technology with the NVIDIA BioNeMo platform to solve complex challenges of drug discovery in the life sciences industry, such as improving productivity in the development process and increasing the speed at which new, life-saving treatments can be brought to market.
-
Journey Medical Corporation Announces U.S. FDA Acceptance Of New Drug Application For DFD-29 For The Treatment Of Rosacea
3/18/2024
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that the FDA has accepted the Company’s New Drug Application (“NDA”) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults.
-
Sanyou Bio And BioGeometry Join Forces To Create A Next-Generation Antibody Drug Discovery Platform Driven By AIGC
3/18/2024
Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement.